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BIOPSY samples  of  head  and  neck  carcinomas  were
investigated with regard to elafin, secretory leukocyte
protease  inhibitor  (SLPI),  interleukin    1-receptor
antagonist  [(IL)1-RA]  and  soluble  tumour  necrosis
factor  a receptor  antagonist  (STNFa RI).  SLPI  and
elafin are serine protease inhibitors produced in the
serous cells of the upper respiratory airways and in
the keratinocytes, respectively. We have now  found
the  presence  of  elafin  and  SLPI  in  squamous  cell
carcinomas of the upper respiratory tract (tonsillar,
hypopharyngeal,  tongue,  mouth  floor,  gingival  and
laryngeal  cancer).  Significantly  higher  amounts  of
SLPI and elafin are present in well-differentiated and
moderately  differentiated  tumours  than  in  poorly
differentiated tumours (p < 0.0001 and p < 0.0015).
Tumour necrosis factor-a and IL-1b have been shown
to stimulate the production of SLPI and elafin. Since
these  cytokines  can  both  be  difficult  to  detect,  we
chose to study their inhibitors, STNFa RI and IL1-RA,
instead. IL1-RA was expressed in highly differentiated
tumours as well as in poorly differentiated ones. No
significant difference was seen between the groups.
STNFa RI  was  only  found  in  very  small  amounts,
sparsely  distributed  in  the  tumours,  and  was  not
related to the degree of differentiation.
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Introduction
Elafin,  or  skin-derived  anti-leukoprotease,  is  a
12.3kDa  cationic  protein  produced  by  keratino-
cytes  that  inhibits  human  leukocyte  elastase  and
proteinase  3.1,2 It  has  a  structural  similarity  to
secretory  leukocyte  proteinase  inhibitor  (SLPI),
which  is  another  locally  produced  serine  protease
inhibitor.3–5 SLPI is a potent inhibitor of leukocyte
elastase and cathepsin G.6,7 Elafin and SLPI differ in
inhibiting activity; elafin inhibits proteinase 3, while
SLPI  exercises  an  inhibitory  effect  on  cathepsin
G.1,8 Both  SLPI  and  elafin  are  produced  locally  in
the lung.9 SLPI is also produced in the serous cells
of  the  upper  respiratory  tract.10,11 Elafin  is
expressed  in  several  epithelia  that  are  continually
subjected  to  inflammatory  stimulus;  for  instance,
the  oral  cavity.  Elafin  is  not  found  in  normal  epi-
dermis,  but  is  produced in  psoriatic and  in  hyper-
proliferative epidermis.1,12 Disturbances in protease-
antiprotease balance are common in many disorders
such as inflammatory diseases, emphysema and also
in  cancer.13–17 Leukocyte  elastase  degrades  extrac-
ellular matrices such as elastin, proteoglycans, colla-
gen  and  fibronectin,  which  could  enhance tumour
invasion  by  tissue  destruction.  In  addition,
increased serum proteolytic activity has been found
in  patients  with  advanced  colon  cancer.18 Data
from a study of mammary epithelial cells and carci-
nomas  suggest  that  elafin  may  be  involved  in  cell
cycle regulation.19 Elafin can be considered to be a
marker  for  regenerative  differentiation.  Both  elafin
and SLPI are potent inhibitors of elastase, which is
frequently  found in the tumour stroma and tumour
cell nests.20,21
Tumour necrosis factor-a (TNF-a) has been found
to be a potent inducer of elafin expression at mRNA
and protein levels.21 Sallenave et al. have shown that
TNF-a and interleukin (IL)-1b both induce SLPI and
elafin  expression.9 Neutrophil  elastase  has  been
found to increase cell-associated SLPI.22
The aims of the present study were to investigate
the expression of SLPI and elafin, and the presence of
elastase (i.e.  leukocyte  invasion)  in  head and  neck
squamous  cell  carcinomas.  We  also  studied  the
occurrence of TNF-a and IL-1b in these carcinomas
since  they  have  been  shown  to  induce  elafin  and
SLPI.9 The  proteinase  inhibitors,  elastase  and  cyto-
kines were investigated in relation to the degree of
histological differentiation and clinical manifestation
of the carcinomas.
Since IL1-b and TNFa can be difficult to detect, we
chose to study their inhibitors, IL1-RA and STNFa RI.
There is an excess of these inhibitors compared with
their  corresponding protein,  which  simplifies  their
detection in tissue.
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Tissues
Archival  biopsy  material  from  the  Department  of
Pathology, used for diagnostic histology, was selected.
The samples were obtained and embedded less than 1
year  before  the  study.  The  tissues  were  fixed  in
buffered 4% formalin for 24h and then embedded in
paraffin. A pathologist classified the head and neck
squamous cell carcinomas. A total of 26 tumours from
different locations were examined. They were classi-
fied  as  well-differentiated,  moderately differentiated
or poorly differentiated. The locations of the tumours
were the larynx, hypopharynx, gingiva, tongue, floor
of  the  mouth  and  tonsils. TNM  classification  was
performed at the Ear, Nose and Throat Department,
Malm¨ o University Hospital to which the patients had
been referred.
The  amount  of  elafin,  SLPI,  elastase,  IL1-RA  and
STNFa RI in the sections was estimated by staining by
a  doctor  and  by  a  technician  on  two  different
occasions  each  (four  times).  The  amounts  were
classified as 3, 2, 1 or 0. The quantifications were in
good agreement with each other.
The spreading of the carcinomas to lymph nodes at
the time of diagnosis was also noted.
Statistics
Spearman’s correlation coefficient was used to com-
pare the amounts of elafin, SLPI, elastase and IL1-RA
in  well-differentiated  and  moderately  differentiated
carcinomas  compared  with  poorly  differentiated
carcinomas.
Immunohistochemical staining
The anti-elafin antibody was tested for cross-reactivity
against  SLPI  at  different  concentrations  using  the
Ouchterlony  immuno-precipitant  technique.  The
same procedure was applied to the anti-SLPI antibody
and elafin.
Before staining, sections were deparaffinized with
xylene, rehydrated with decreasing concentrations of
methanol,  and  finally  rinsed  in Tris-buffered  saline
(TBS) (0.05M Tris, 0.145M NaCl; pH 7.6). To quench
endogenous peroxidase activity, sections were incu-
bated with 0.3% H2O2in methanol for 30min at room
temperature, followed by rinsing in TBS for 3 ´ 5min.
Slides were then incubated with normal rabbit serum
diluted 1/20  to block unspecific  staining.  SLPI was
detected using a goat anti-SLPI antibody (produced at
our own laboratory) diluted 1/2000. The slides were
then incubated with a biotinylated rabbit anti-goat IgG
(Vector Laboratories, Inc., Burlingame,  USA) (5mg/l
buffer)  for  30min  followed  by  another  3 ´ 5min
washing in the same buffer, and then incubated with
a Vectastain ABC kit (Vector Laboratories, Inc.). After
rinsing, substrate reactions were performed by incu-
bation with 0.06% diaminobenzidine tetrahydrochlor-
ide in TBS containing 0.01% H2O2 for 5min. After final
rinsing  in TBS,  sections were  counterstained, dehy-
drated, cleared and mounted. Control sections were
incubated  with  adsorbed  antigen  or  normal  goat
serum. The sections were counterstained with haema-
toxylin (Mayer hematoxylin, Histolab., Gothenburg).
To demonstrate the presence of elafin, a primary
rabbit  anti-human  antibody  (1/3000)  (Peptide  Insti-
tute, Japan; Scientific Marketing Association, UK) was
used. As a secondary antibody, a biotinylated goat anti-
rabbit  IgG  was  applied  (Vector  Laboratories,  Inc.).
IL1-RA was detected with a primary rabbit anti-human
antibody  (1/500–1/1000)  (produced  at  our  own
laboratory),  and  a  biotinylated  goat  anti-rabbit  IgG
was used as the secondary antibody. STNFa RI was
visualized with a primary rabbit anti-human antibody
(1/500–1/1000)  (produced at  our  own  laboratory),
and a biotinylated goat anti-rabbit IgG as the second-
ary antibody, incubated overnight. To visualize elas-
tase, a rabbit anti-human leukocyte elastase antibody
was used (1/2000), and a biotinylated goat anti-rabbit
IgG antibody was used as a secondary antibody. The
procedures were otherwise performed as described
for SLPI except for elafin, where the control sections
not  were  subjected  to  adsorbed  antigen  since  the
antibodies were purchased. Control sections in elas-
tase  were  subjected  to  a  mixture  of  antigen  and
antibody.
Results
No cross-reactivity was observed between anti-elafin
antibodies and SLPI, or between anti-SLPI antibodies
and elafin.
The classifications 2 and 3 were in agreement in all
but three cases. No sections classified as 2 or 3 were
classified as 1 or 0.
Well-differentiated carcinomas
Elafin
Elafin was expressed in most squamous tumour cell
nests  but  there  were  also  some  cells  that  did  not
express the inhibitor. The staining was most promi-
nent in areas with well-differentiated cells. Separate
positive  tumour  cells  could be seen  located in  the
tissue in between. Elafin was sporadically expressed
in normal squamous epithelium where the carcinoma
was  not  established.  Elafin  was  expressed  at  all
tumour  locations  examined  (larynx,  hypopharynx,
tonsils, tongue, gingiva and mouth floor) (Fig. 1). The
quantity  of  elafin  was  significantly  higher  in  well-
differentiated and moderately differentiated carcino-
mas  than  in  poorly  differentiated  carcinomas  (p <
0.0001) (Table 1).
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Table 1. Quantification of elafin, SLPI, elastase and IL1-RA in head and neck carcinomas
Carcinoma Elafin* SLPI* Elastase IL-1RA Carcinoma location
Well-differentiated 3 2 Tonsils
3, 3 3, 2 1, 3 3 Mouth floor or gingiva
3, 3 3, 2 1, 2 3 Larynx
Hypopharynx
3 3 3 3 Tongue
Moderately differentiated 3, 1, 3 3, 1 2, 3, 2 3, 3 Tonsils
1, 1 1, 0 2 Mouth floor or gingiva
2, 1 3, 1 1, 2 3, 3 Larynx
0, 2 0, 1 2, 3 3 Hypopharynx
1 3 3 Tongue
Poorly differentiated 0, 0, 1 2, 1, 1 2, 1, 2 3, 3 Tonsils
1 Mouth floor or gingival
1, 1 0, 1 1, 2 2 Larynx
1, 1, 1 0, 0 2, 3 3 Hypopharynx
Tongue
Well-differentiated and moderately differentiated carcinomas are seen to contain significantly more elafin (*p < 0.0001) than poorly differentiated
carcinomas.  Well  and  moderately  differentiated  carcinomas  also  contain  significantly  higher  amounts  of  SLPI  (*p <  0.0015)  than  poorly
differentiated carcinomas. The amounts of elastase and IL1-RA do not differ due to the degree of differentiation. The carcinomas were classified
as 0, 1, 2 and 3, where 0 represents no positive staining and 3 represents the highest degree of positive staining.
FIG. 1. Well-differentiated carcinoma in tonsils where several
metaplastic cells display a positive immunoreaction to elafin
(´ 200).
FIG.  2.  Well-differentiated  carcinoma  of  the  floor  of  the
mouth. Tumour cell nests show distinct positive staining for
SLPI (´ 500).
FIG. 3. A section from the same patient as in Fig. 1, showing
a positive immunoreaction to IL1-RA in a tumour cell nest (´
200).
FIG. 4. A section from a carcinoma of the tongue displaying
a  positive  immunoreaction  to  elastase.  Positive  elastase
staining is seen dispersed in the stroma but with accumula-
tion in the tumour cell nest (´ 500).SLPI
The expression of SLPI was similar to that of elafin
except that there seemed to be a smaller amount of
SLPI  than  elafin  (Fig.  2).  SLPI  was  expressed at  all
tumour  locations.  The  amount  of  SLPI  was  sig-
nificantly higher in well-differentiated and moderately
differentiated  carcinomas  than  in  poorly  differen-
tiated carcinomas (p < 0.0015) (Table 1).
IL1-RA
The  distribution  of  IL1-RA  coincided  with  that  of
SLPI and elafin,  but  the quantity  of IL1-RA did not
differ between the degrees of tumour differentiation
(Fig. 3).
Elastase
Elastase was found in various quantities at all tumour
locations.  The  protease  was  diffusely  distributed
throughout the tissues, although a slight concentra-
tion  of  elastase was observed close  to tumour  cell
nests (Fig. 4).
STNFa RI
Sparse amounts of STNFa RI were found in separate




All but one sample contained elafin-positive tumour
cell  nests.  In  areas with  poorly  differentiated  cells,
elafin was absent or very sparse.
SLPI
All but two samples showed positive staining for SLPI.
SLPI expression corresponded to that of elafin.
Elastase
The  samples  demonstrated  the  same  pattern  of
expression as in well-differentiated carcinomas.
IL1-RA
No differences were seen regarding the amount or
location of IL1-RA compared with well-differentiated
carcinomas.
STNFa RI
Some carcinomas contained a few tumour cells with




Considerably  less  tumour  cells  were  positively
stained. At some locations, only  isolated cells were
diffusely  spread  throughout  the  tissue. Two  of  the





FIG.  5.  (A)  Poorly  differentiated carcinoma  of  the  tonsils.
Some of the tumour cells display a positive immunoreaction
to  elafin in the tumour cell  nest,  as  demonstrated in this
section. (B) The same section showing SLPI, (C) the same
tumour cell nest showing IL1-RA, and (D) the same tumour
cell nest showing elastase (´ 200).
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SLPI  expression  followed  the  same  pattern  as  for
elafin. Three samples did not contain any SLPI at all
(Fig. 5B).
IL1-RA
All carcinomas stained positive for IL1-RA and showed
the same pattern of expression as well-differentiated
and moderately differentiated tumours (Fig. 5C).
Elastase
The  samples  demonstrated  the  same  pattern  of
expression  as  in  well-differentiated  and  moderately
differentiated carcinomas (Fig. 5D).
STNFa RI
A small number of carcinomas stained positively in a
few  tumour  cells  randomly  distributed  (data  not
shown).
Elafin and SLPI in carcinomas with local lymph
node metastases
Three out of eight patients with carcinomas contain-
ing SLPI and elafin classified as 3 or 2 had carcinomas
in  local  lymph  nodes.  Seven  out  of  12  patients
classified as 1 or 0 had tumours spread to local lymph
nodes (Table 2).
Discussion
The presence of protease inhibitors and their target
enzymes in tissues indicates an ongoing reaction due
to  hostile  agents  in  order to  protect the host. The
maintenance of protease/protease inhibitor balance is
of  vital  importance  in  protecting  against  extensive
tissue destruction. This balance is also sustained in
cancer. One could argue that leukocyte invasion and
degranulation in tumours probably protects the host
from  malignant  cells.  A  side-effect  of  proteolytic
activity is degradation of surrounding tissue, which
could enhance tumour spread. Therefore, it is impor-
tant that a relevant local inhibitor is available. Another
important function could be as an inhibitor of the cell
cycle,  which  has  been  demonstrated  in  mammary
epithelial cells and carcinomas by the down-regula-
tion of elafin mRNA in S-phase in normal cells.19
IL-1b and TNFa are cytokines known to participate
in protein induction. SLPI and elafin have been shown
to be generated by these cytokines.9,21 To overcome
the difficulties in detection of these substances due to
the small amounts present in tissues, we studied their
inhibitors (IL1-RA and STNFa RI) instead, which are
usually found in excess and are easier to detect.
All sterile tissue is devoid of elafin. Epithelial tissue
subjected to constant inflammatory stimuli, such as
the oral cavity or genital tract, contains elafin. Elafin is
not present in normal skin, whereas keratinocytes in
psoriatic scales produce the inhibitor.1,12 SLPI, which
is  expressed  in  serous  cells  of  the  mucosa  of  the
respiratory tract and in several other glandular epithe-
lia,  has  been  shown  to  be  inducible  in  keratino-
cytes.10,11,23 Both  these  inhibitors  probably  offer
protection  against  activated  leukocyte-induced  and
elastase-induced cell  detachment, which could pro-
tect against tumour invasion in adjacent tissue.
The locations of SLPI and elafin in squamous cell
carcinomas  coincide,  although  slightly  less  SLPI  is
present than elafin. The amounts of these inhibitors
are correlated to the degree of tumour differentiation.
Well-differentiated and moderately differentiated car-
cinomas  contain  more  SLPI  and  elafin  than  poorly
differentiated carcinomas. Positive staining was seen
in  cells  with  distinct  squamous  differentiation.  In
moderately differentiated carcinomas, only well-differ-
entiated cells  demonstrated SLPI  and  elafin.  Poorly
differentiated cells did not stain positively for either of
the inhibitors.
Since  there  was  no  difference  between  elastase
presence  in  well-differentiated,  moderately  differ-
entiated and poorly differentiated tumours, one might
assume that protection against cell detachment, and
hence  tumour  spread,  is  inferior  in  poorly  differ-
entiated  carcinomas.  It  seems  that  even  poorly
differentiated carcinomas were able to produce IL1-
RA. It appears that although poorly differentiated cells
are  able  to  express  IL1-RA,  only  well-differentiated
tumour  cells  can  respond  and  produce  SLPI  and
elafin.  The  same  is  true  of  elastase,  which  also
stimulates  their  production.9 STNFa RI  was  only
found  in  isolated  tumour  cells,  which  could  be
attributed to the immunohistological techniques avail-
able at our laboratory.
There are many chemical processes that contribute
to cancer development and spread. Protection against
cell  detachment  might  be  one  mechanism  against
cancer  progression.  Patients  with  poorly  differen-
tiated tumours and low amounts of or no inhibitors
had  developed  lymph  node  metastase  to  a  higher
degree than the other patients.
In conclusion, the ability to produce SLPI and elafin
coincided with well-differentiated tumours and with
less  spread  to  local  lymph  nodes  at  the  time  of
diagnosis. A clinical implication of these results could
be that the expression of these inhibitors could be
Elafin, SLPI, IL1-RA and STNFa RI in head and neck squamous cell carcinomas
Mediators of Inflammation · Vol 11 · 2002 11
Table 2. Elafin and SLPI in carcinomas with local lymph node
metastases
Classification Elafin and SLPI
2, 3 0, 1
Lymph node carcinomas 3 (n = 8) 7 (n = 12)
Three out of eight patients classified (elafin and SLPI) as 2 or 3 had
carcinomas  in  lymph  nodes  and  seven  out  of  twelve  patients
classified  as 0 or  1  had  tumour spread  to  local  lymph  nodes.  Six
patients out of twenty-six were not TNM classified.used  as  a  prognostic  tool  and  maybe  predict  the
outcome of the disease.
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